

28 March 2017

EMA/204715/2012 Rev 2\* - Track-change version versus revision 1

## Guideline on good pharmacovigilance practices (GVP)

### Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev 2)

Date for coming into effect of first version	1 March 2014
Date for coming into effect of Revision 1	28 April 2014
Draft Revision 2* finalised by the Agency in collaboration with Member States	6 March 2017
Draft agreed by the EU Network Pharmacovigilance Oversight Group (EU-POG)	23 March 2017
Draft adopted by Executive Director as final*	28 March 2017
Date for coming into effect of Revision 2**	31 March 2017

\*Note: Revision 2 includes the following:

- Changes to XVI.A. to delete the description of routine risk minimisation tools as they are detailed in GVP Module V;
- Changes to XVI.C. to add a paragraph to emphasise the role of Member States in the implementation of risk minimisation measures;
- Changes to XVI.C.1. and XVI.C.2. to add text clarifying the responsibility of the marketing authorisation holder to implement all conditions or restrictions with regard to the safe use of the product in a particular territory;
- Changes to XVI.C.1.1.3. to clarify that patient alert cards included in the package are part of the product information;
- Editorial amendments throughout the Module to increase the clarity of the guidance and the consistency of its presentation with other GVP Modules.

This revision of the Module was not subject to public consultation because it concerns amendments with the specific objective to align its content with the changes in or adding text from GVP Module V Revision 2, which was subject to public consultation.

**This track-change version identifies the majority of changes introduced during the revision of this Module. This track-change version is published for transparency purposes and must not be taken or quoted as the final version.**

**\* For this reason, the timetable above, and in particular the date of coming into effect, apply only the clean version published as final.**

See websites for contact details

European Medicines Agency [www.ema.europa.eu](http://www.ema.europa.eu)  
Heads of Medicines Agencies [www.hma.eu](http://www.hma.eu)

The European Medicines Agency is  
an agency of the European Union



For the final version of this Module and any future updates, please see the GVP webpage of the Agency's website.

## Table of contents

<b>XVI.A. Introduction</b>	<b>4</b>
<b>XVI.B. Structures and processes</b>	<b>5</b>
XVI.B.1. General principles	5
XVI.B.2. Risk minimisation measures	6
XVI.B.2.1. Educational programme	7
XVI.B.2.1.1. Educational tools	7
XVI.B.2.1.1.1. Educational tools targeting healthcare professionals	8
XVI.B.2.1.1.2. Educational tools targeting patients and/or carers	8
XVI.B.2.2. Controlled access programme	8
XVI.B.2.3. Other risk minimisation measures	9
XVI.B.2.3.1. Controlled distribution system	9
XVI.B.2.3.2. Pregnancy prevention programme	9
XVI.B.2.3.3. Direct health care professional communication (DHPC)	10
XVI.B.3. Implementation of risk minimisation measures	10
XVI.B.4. Effectiveness of risk minimisation measures	11
XVI.B.4.1. Process indicators	12
XVI.B.4.1.1. Reaching the target population	12
XVI.B.4.1.2. Assessing clinical knowledge	13
XVI.B.4.1.3. Assessing clinical actions	13
XVI.B.4.2. Outcome indicators	14
XVI.B.5. Coordination	14
XVI.B.6. Quality systems of risk minimisation measures	15
<b>XVI.C. Operation of the EU network</b>	<b>15</b>
XVI.C.1. Roles and responsibilities within the EU regulatory network	16
XVI.C.1.1. The European Medicines Agency	16
XVI.C.1.2. The Pharmacovigilance Risk Assessment Committee (PRAC)	16
XVI.C.1.3. Competent authorities in Member States	16
XVI.C.2. Roles and responsibilities of the marketing authorisation holder or applicant in the EU	18
XVI.C.3. Healthcare professionals and patients	19
XVI.C.4. Impact of risk minimisation measures effectiveness on RMP/PSUR in the EU	19
XVI.C.5. Transparency	20
<b>XVI. Appendix 1. Key elements of survey methodology</b>	<b>22</b>
XVI.App1.1. Sampling procedures and recruitment strategy	22
XVI.App1.2. Design and administration of the data collection instrument(s)	23
XVI.App1.3. Analytical approaches	23
XVI.App1.4. Ethics, privacy and overall study feasibility	24

## XVI.A. Introduction

Risk minimisation measures are interventions intended to prevent or reduce the occurrence of adverse reactions associated with the exposure to a medicine, or to reduce their severity or impact on the patient should adverse reactions occur. Planning and implementing risk minimisation measures and assessing their effectiveness are key elements of risk management.

The guidance provided in this Module should be considered in the context of the wider GVP guidance, in particular in conjunction with [GVP Module V](#).

Risk minimisation measures may consist of routine risk minimisation or additional risk minimisation measures. Routine risk minimisation is applicable to all medicinal products, and involves the use of [the following different](#) tools, which are described in detail in [GVP Module V](#):

- ~~• the summary of product characteristics (SmPC);~~
- ~~• the package leaflet;~~
- ~~• the labelling;~~
- ~~• the pack size and design;~~
- the legal (prescription) status of the product.

Safety concerns of a medicinal product are normally adequately addressed by routine risk minimisation measures (see [GVP Module V](#)). In exceptional cases however, routine risk minimisation measures will not be sufficient for some risks and additional risk minimisation measures will be necessary to manage the risk and/or improve the risk-benefit balance of a medicinal product. This module provides particular guidance on the use of additional risk minimisation measures, including the selection of tools and the evaluation of their effectiveness. In specific circumstances, however, the [effectiveness evaluation](#) may also apply to routine risk minimisation measures associated with safety concern(s) which are described in the [summary of product characteristics \(SmPC\) and package leaflet \(PL\) /PII](#) (e.g. the SmPC provides guidance for clinical actions beyond routine standards of clinical care for either the risk itself or management of the target population). [In these circumstances, the guidance provided in this Module on effectiveness evaluation also applies to routine risk minimisation measures.](#)

On the basis of the safety concerns described in the safety specification (see [GVP Module V](#)), the appropriate risk minimisation measures should be determined. Each safety concern needs to be individually considered and the selection of the most suitable risk minimisation measure should take into account the seriousness of the potential adverse reaction(s) and its severity (impact on patient), its preventability or the clinical actions required to mitigate the risk, the indication, the route of administration, the target population and the healthcare setting for the use of the product. A safety concern may be addressed using more than one risk minimisation measure, and a risk minimisation measure may address more than one safety concern.

Directive 2001/83/EC indicates that the marketing authorisation holder shall “monitor the outcome of risk minimisation measures which are contained in the risk management plan or which are laid down as conditions of the marketing authorisation pursuant to Articles 21a, 22 or 22a” (DIR Art 104 (2) (d)). The Directive and Regulation (EC) No 726/2004 also include provisions for the Agency and the national competent authorities to monitor the outcome of risk minimisation measures which are contained in the risk management plans (RMPs) or measures that are laid down as conditions.

This Module provides guidance on the principles for:

- ~~The~~ development and implementation of additional risk minimisation measures, including examples of risk minimisation tools;
- ~~The~~ evaluation of the effectiveness of risk minimisation measures.

~~Part~~ XVI.B. describes the development, implementation and co-ordination of risk minimisation measures and the general principles of the evaluation of their effectiveness. ~~Part~~ XVI.C. considers the application of those measures and principles in the setting of the EU regulatory network.

In this Module, all applicable legal requirements are referenced in the way explained in the GVP Introductory Cover Note and are usually identifiable by the modal verb "shall". Guidance for the implementation of legal requirements is provided using the modal verb "should".

## **XVI.B. Structures and processes**

### ***XVI.B.1. General principles***

Risk minimisation measures aim to optimise the safe and effective use of a medicinal product throughout its life cycle. The risk-benefit balance of a medicinal product can be improved by reducing the burden of adverse reactions or by optimising benefit, through targeted patient selection and/or exclusion and through treatment management (e.g. specific dosing regimen, relevant testing, patient follow-up). Risk minimisation measures should therefore guide optimal use of a medicinal product in ~~medical-clinical~~ practice with the goal of supporting the provision of the right medicine, at the right dose, at the right time, to the right patient and with the right information and monitoring.

The majority of safety concerns are addressed by routine risk minimisation measures (see **GVP Module V**). Exceptionally, for selected important risks, routine risk minimisation may be considered insufficient and additional risk minimisation measures may be deemed ~~to be~~ necessary. In determining if additional risk minimisation activities are needed, safety concerns should be prioritised in terms of frequency, seriousness, severity, impact on public health and preventability. Careful consideration should then be given to whether the goal can be reached with routine minimisation activities, and, if not considered ~~feasible~~ sufficient, which additional minimisation measure(s) is (are) the most appropriate. Additional risk minimisation measures should focus on the most important, preventable risks and the burden of imposing additional risk minimisation should be balanced with the benefit for patients.

A variety of tools are currently available for additional risk minimisation. This field is continuously developing, and new tools are likely to be developed in the future. Technology advances, such as interactive web-based tools may gain prominence ~~in the future~~ in addition to the paper-based educational materials.

Successful implementation of additional risk minimisation measures requires contributions from all ~~impacted~~ stakeholders, including marketing authorisation applicants ~~/or~~ holders, patients and healthcare professionals. The performance of these measures in healthcare systems requires assessment to ensure that their objectives are fulfilled and that the measures in place are proportionate taking account of the risk-benefit balance of the product and the efforts required of healthcare professionals and patients to implement the measures. It is therefore important to ensure that additional risk minimisation measures, including assessment of their effectiveness, do not introduce undue burden on the healthcare delivery system, the marketing authorisation holders, the regulators, and, most importantly, on the patients. To this aim, they should have a clearly defined objective relevant to the minimisation of specific risks and/or optimisation of the risk-benefit balance. Clear objectives and defined measures of success with milestones need to guide the development of

additional risk minimisation measures, and close monitoring of both their implementation and ultimate effectiveness is necessary. The nature of the safety concern in the context of the risk-benefit balance of the product, the therapeutic need for the product, the target population and the required clinical actions for risk minimisation are factors to be considered when selecting risk minimisation tools and [developing](#) an implementation strategy to accomplish the desired public health outcome. The evaluation of effectiveness should facilitate early corrective actions if needed and may require [modifications](#) over time. It is recognised that this is an evolving area of medical sciences with no universally agreed standards and approaches. Therefore, it is important to take advantage of any relevant elements of [methodology-methods](#) from pharmacoepidemiology and other disciplines, such as social/behavioural sciences and qualitative research methods.

The introduction of additional risk minimisation should be considered as a “programme” where specific tools, together with an implementation scheme and evaluation strategy are developed. The description of risk minimisation measures, an integral part of the RMP (see [GVP Module V](#)), should therefore give appropriate consideration to the following points:

- Rationale: When additional risk minimisation measure(s) are introduced –a rationale should be provided for those additional measures;
- Objectives: Each proposed additional risk minimisation measure(s) should include defined objective(s) and a clear description of how and which safety concern is addressed with the proposed additional risk minimisation measure(s);
- Description: This section of the RMP should describe the selected additional risk minimisation measures, including tools that will be used and key elements of content;
- Implementation: This section of the RMP should provide a detailed proposal for the implementation of additional risk minimisation measures (e.g. setting and timing or frequency of intervention, details of the target audience, plan for the distribution of educational tools; how the action will be coordinated where more than one marketing authorisation holder is involved);
- Evaluation: This section of the RMP should provide a detailed plan with milestones for evaluating the effectiveness of additional risk minimisation measures in process terms and in terms of overall health outcome measures (e.g. reduction of risk).

### ***XVI.B.2. Risk minimisation measures***

Risk minimisation measures aim to facilitate informed decision making to support risk minimisation when prescribing, [supplying-dispensing](#) and/or using a medicinal product. While routine measures are applied to every medicinal product (see [details in GVP Module V](#)), additional risk minimisation activities should only be introduced when they are –deemed to be essential for the safe and effective use of the medicinal product (see also [XVI.C.1+](#)) and should be developed and provided by suitably qualified people.

Additional risk minimisation measures may differ widely in purpose, design, target audience and complexity. These measures might be used to guide appropriate patient selection with the exclusion of patients where use is contraindicated, to support on-treatment monitoring relevant to important risks and/or management of an adverse reaction–[once detected](#). Additionally, specific measures may be developed to minimise the risk of medication error<sup>1</sup> and/or to ensure appropriate administration of the product where it is not feasible to achieve this through the product information and labelling alone.

---

<sup>1</sup> [EMA Pharmacovigilance Risk Assessment Committee. Good practice guide on risk minimisation and prevention of medication errors \(-EMA/606103/2014\). 18 November 2015.](#)

~~Section~~ XVI.B.2. describes additional risk minimisation measures that may be considered in addition to the routine measures, including:

- ~~Educational-educational~~ programmes;
- ~~Controlled-controlled~~ access programmes;
- ~~Other-other~~ risk minimisation measures.

### **XVI.B.2.1. Educational programme**

Educational programmes are based on targeted communication with the aim to supplement the information in the ~~summary product characteristics (SmPC)~~ and ~~package leafletPL~~. Any educational material should focus on actionable goals and should provide clear and concise messages describing actions to be taken in order to prevent and minimised selected ~~safety concernsrisks~~.

The aim of an educational programme is to improve the use of a medicine by positively influencing the actions of healthcare professionals and patients towards minimising risk. Educational materials should therefore be built on the premise that there is an actionable recommendation for targeted education and that applying this measure is considered essential for minimising an important risk and/or for optimisation of the risk-benefit balance. In the context of an educational programme, the tools can have several different target audiences, can address more than one safety concern and can be delivered using a combination of tools and media (e.g. paper, audio, video, web, in-person training). Ideally, educational materials should be available in a range of formats so as to ensure that access is not limited by ~~a~~ disability or access to the internet. When feasible the appropriateness of the tool and media for the target audience (e.g. suitable language, pictures, diagrammes, or other graphical support) should be user tested in advance, in order to optimise the success of the implementation phase.

The content of any educational material should be fully aligned with the currently approved product information for a medicinal product, such as the SmPC and ~~package leafletPL~~, and should add rather than duplicate SmPC and ~~package leafletPL~~ information. Promotional elements, either direct or veiled (e.g. logos, product brand colours, suggestive images and pictures), should not be included and the focus of the educational material should be on the risk(s) related to the product and the management of those risk(s) requiring additional risk minimisation.

Any educational programme should be completely separated from promotional activities and contact information of physicians or patients gathered through educational programmes should not be used for promotional activities.

The educational tools described below can be considered individually or in combinations while developing an educational programme for the purpose of additional risk minimisation.

#### **XVI.B.2.1.1. Educational tools**

An educational tool should have a clearly defined scope and should include unambiguous statement(s) regarding the important risk(s) of concern to be addressed with the proposed tool, the nature of such risk(s) and the specific steps to be taken by healthcare professionals and/or patients in order to minimise those risks. This information should focus on clearly defined actions related to specific safety concerns described in the RMP and should not be ~~unnecessarily~~ diluted by including information that is not immediately relevant to the safety concern and that is ~~already~~ adequately presented in the SmPC or package leaflet. Educational tools should refer the reader to the SmPC and the package leaflet. In addition to an introductory statement that the educational material is essential to ensure the safe and

effective use and appropriately manage important selected risks, elements for inclusion in an educational tool could provide:

- guidance on prescribing, including patient selection, testing and monitoring;
- guidance on the management of such risks (to healthcare professionals and patients or carers);
- guidance on how and where to report adverse reaction of special interest.

Further guidance on the responsibilities of the applicant or marketing authorisation holder and the competent authorities are provided in [XVI.C.1.1 of this Module](#).

#### ***XVI.B.2.1.1.1. Educational tools targeting healthcare professionals***

The aim of any educational tool targeting a healthcare professional should be to deliver specific recommendation(s) on the use (what to do) and/or contraindication(s) (what not to do) and/or warnings (e.g. how to manage [an](#) adverse reaction(s)) associated with the medicine and the specific important risks needing additional risk minimisation measures, including:

- selection of patients;
- treatment management such as dosage, testing and monitoring;
- special administration procedures, or the dispensing of a medicinal product;
- details of information which needs to be given to patients.

The format of a particular tool [will-should](#) depend upon the message to be delivered. For example, where a number of actions are needed before writing a prescription for [an individual](#) patient, a checklist may be the most suitable format. A brochure may be more appropriate to enhance awareness of specific important risks with a focus on the early recognition and management of adverse reactions, while posters for display in certain clinical environments can include helpful treatment or dosage reference guides. Other formats may be preferable, depending on the [scope-objective](#) of the tool.

#### ***XVI.B.2.1.1.2. Educational tools targeting patients and/or carers***

The aim of tools targeting patients [and/or carers](#) should be to enhance their awareness of [patients-or their carers-on](#) the early signs and symptoms of specific adverse reactions causing the need for additional risk minimisation measures and on the best course of action to be taken should any of those [sign or](#) symptoms occur. If appropriate, a patient's educational tool could be used to provide information on the correct administration of the product and to remind the patient about an important activity, for example a diary [for-posesologyof dosing](#) or [a](#) diagnostic procedures that need to be carried out and recorded by the patient and eventually discussed with healthcare professionals, to ensure that any steps required for the [safe and](#) effective use of the product are adhered to.

##### Patient alert card

The aim of this tool should be to ensure that special information regarding the patient's current therapy and its important risks (e.g. potential life-threatening interactions with other therapies) is held by the patient at all times and reaches the relevant healthcare professional [as-appropriatewhen needed](#). The information should be kept to the minimum necessary to convey the key minimisation message(s) and the required [mitigating](#)-action, in any circumstances, including emergency. Ability to carry [the patient alert card](#) with ease (e.g. [it](#) can be fitted in a wallet) should be a key [design](#) feature of this tool.



### **XVI.B.2.2. Controlled access programme**

A controlled access programme consists of interventions seeking to control access to a medicinal product beyond the level of control ensured by routine risk minimisation measures, i.e. [the](#) legal status. Since a controlled access programme has large implications for all stakeholders, the use of such a programme should be limited and should be guided by a clear therapeutic need for the product based on its demonstrated benefit (e.g. it treats a serious disease without alternative therapies; it treats patients who have failed on existing therapies), the nature of the associated risk (e.g. risk is life-threatening), and [the likelihood that whether](#) this risk [is expected to can](#) be managed by [the interventions such a programme](#). Therefore, controlled access should only be considered as a tool for minimising an important risk with significant public health or individual patient impact for a product with clearly demonstrated benefits but which would not otherwise be available without a programme where patient access is contingent on fulfilling one or more requirements prior to a product being prescribed or dispensed in order to assure its safe use.

Examples of requirements that need to be fulfilled before the product is prescribed and/or dispensed and/or used in a controlled access programme are listed below (they may be included individually or in combination):

- [Specific-specific](#) testing and/or examination of the patient to ensure compliance with strictly defined clinical criteria;
- [Prescriberprescriber](#), dispenser and/or patient documenting their receipt and understanding of information on the serious risk of the product;
- [Explicit-explicit](#) procedures for systematic patient follow-up through enrolment in a specific data collection system e.g. patient registry;
- [Medicines-medicines](#) made available for dispensing only [to-by Pp](#) pharmacies [which-that](#) are registered and approved to dispense the product.

On occasions, a requirement to test or to monitor a patient in a specific way can also be used as a controlled access tool. For example, monitoring of the patient's health status, laboratory values or other characteristic [\(e.g. an ECG\)](#) prior to and/or during treatment, e.g. [electrocardiogram](#), liver function tests, regular blood tests, pregnancy tests (which can be part of a pregnancy prevention programme). Measures should be put in place to ensure that monitoring takes place according to the SmPC where this is critical to risk-benefit balance of the product.

### **XVI.B.2.3. Other risk minimisation measures**

#### **XVI.B.2.3.1. Controlled distribution systems**

A controlled distribution system refers to the set of measures implemented to ensure that the stages of the distribution chain of a medicinal product are tracked up to the prescription and/or pharmacy dispensing the product. Orders and shipments of product from a single or multiple identified distribution points [in the EU](#) facilitate traceability of the product. For instance, this sort of measures could be considered for those products controlled in each [Member Statecountry](#) under the respective national legislations [about to prevent the](#) misuse and abuse of medicines.

#### **XVI.B.2.3.2 Pregnancy prevention programme**

A pregnancy prevention programme (PPP) is a set of interventions aimed [eding to at minimise-minimising](#) pregnancy exposure during treatment with a medicinal product with known or potential teratogenic

effects. The scope of such a programme is to ensure that female patients are not pregnant when starting therapy ~~or~~ and do not become pregnant during the course of and/or soon after stopping the therapy. It could also target male patients when use of a medicinal product by the biological father might have a negative effect on pregnancy outcome.

A PPP combines the use of educational tools with interventions to control appropriately access to the medicine. Therefore, the following elements should be considered individually and/or in combination in the development of a PPP:

- ~~Educational~~ educational tools targeting healthcare professionals and patients to inform ~~on~~ about the teratogenic risk and required actions to minimise this risk (e.g. guidance on the need to use more than one method of contraception and guidance on different types of contraception, yes; information included for the patient on how long to avoid pregnancy after treatment is stopped, +; information for when the male partner is treated);
- ~~Controlled~~ controlled access at prescribing or dispensing level to ensure that a pregnancy test is carried out and negative results are verified by the healthcare professional before prescription or dispensing of the medicinal product ~~(and)~~;
- ~~Prescription~~ prescription limited to a maximum of 30 ~~days~~ days' supply;
- ~~Counselling~~ counselling in the event of inadvertent pregnancy and evaluation of the outcome of any accidental pregnancy.

The design and implementation of a pregnancy registry (as a stand-alone activity or as part of a pregnancy prevention programme) should also be considered for universal enrolment of patients who become pregnant during treatment or within an appropriate time ~~from~~ after the end of treatment (e.g. 3 months). Use of this systematic tool to collect pregnancy outcome information can be helpful in assessing the effectiveness of the pregnancy prevention programme and/or in facilitating further characterisation of the risk, particularly in the early period post authorisation when human pregnancy data may be very limited and/or when the potential concern may be based on non-clinical data alone.

### **XVI.B.2.3.3. Direct health care professional communication (DHPC)**

A direct healthcare professional communication (DHPC) is a communication intervention by which important information is delivered directly to individual healthcare professionals by a marketing authorisation holder or by a competent authority, to inform them of the need to take certain actions or adapt their practices in relation to a medicinal product (see GVP Annex I). For example, a DHPC may aim at adapting prescribing behaviour to minimise particular risks and/or to reduce the burden of adverse reactions with a medicinal product. Situations where dissemination of a DHPC should be considered are detailed in GVP Module XV.

### **XVI.B.3. Implementation of risk minimisation measures**

Additional risk minimisation measures can consist of one or more interventions that should be implemented in a sustainable way in a defined target group. Careful consideration should be given to both the timing and frequency of any intervention and the procedures to reach the target population. For example, a one-off distribution of educational tools may be insufficient to ensure that all potential prescribers and/or users, including new prescribers and users, are reached. Additional periodic re-distribution of the tools might be necessary. Conversely, educational materials required at the time of launch of a new medicinal product may no longer be necessary or relevant once ~~it has~~ they have been available for a number of years (see GVP Module V). Because risk minimisation measures serve different purposes specific objectives, some measures such as alert cards, controlled access

programmes and pregnancy prevention programmes, will usually apply to all future applications for the same medicinal product, whilst others, such as DHPCs and training materials, may not necessarily be needed for all future applications. The appropriateness of each measure and whether these will be required for the future applications for the same medicinal products should be carefully considered at the time of authorisation of the product (and made clear in the RMP). Careful consideration should be given to the layout and content of the educational tools to ensure a clear distinction from any promotional material distributed. Submission of educational material for review by the ~~national~~ competent authority should be separate from submission of promotional material and a ~~covering~~ letter should clearly state whether the materials are promotional or educational. Furthermore, educational tools should be distributed separately from promotional materials as a 'stand-alone' communication and it should be clearly stated that the tools are not promotional material, but rather have risk minimisation purposes. Quality assurance mechanisms should ensure that the distribution systems in place are fit for purpose and auditable.

#### **XVI.B.4. Effectiveness of risk minimisation measures**

Evaluating the effectiveness of additional risk minimisation measures is necessary to establish whether an intervention has been effective or not, and if not why ~~not~~ and which ~~-~~corrective actions are necessary. The evaluation should be performed for the additional risk minimisation tools individually and for the risk minimisation programme as a whole.

Effectiveness evaluation should be conducted at the most appropriate time, accounting for time required for launch of ~~intervention~~the risk minimisation measures, ~~the~~ estimated use of the product ~~into by~~ the healthcare system and other relevant circumstances.

Periodic review of the effectiveness of one or more specific tools or the overall programme, as appropriate, should be ~~also~~ planned. Time points of particular relevance are as follows:

- after initial implementation of a risk minimisation programme (e.g. within 12-18 months), in order to allow the possibility of amendments, should they be necessary;
- in time for the evaluation of the renewal of a marketing authorisation; ~~and~~

~~whenever~~Whenever effectiveness is evaluated, careful consideration should be given on the need for continuing with the additional risk minimisation measure.

Effectiveness evaluation should address different aspects of the risk minimisation, ~~i.e.~~ the process itself (i.e. to what extent the programme has been implemented as planned), its impact on knowledge and behavioral changes in the target audience (i.e. the measure(s) in affecting behavioural change), and the outcome (i.e. to what extent the predefined objectives of risk minimisation were met, in the short and long term). In designing an evaluation strategy, due consideration needs to be made toward what aspects of process and outcomes can be realistically measured in order to avoid the generation of inaccurate or misleading data or placing an undue burden on the healthcare system or other stakeholders. ~~The time~~ ~~point~~ ~~effor~~ assessing each aspect of the intervention as well as setting of realistic metrics on which the effectiveness of the tool is judged, should also be carefully considered and planned ~~-~~ prior to initiation.

To evaluate the effectiveness of additional risk minimisation measures two categories of indicators should be considered:

- ~~Process~~ ~~process~~ indicators;
- ~~Outcome~~ ~~outcome~~ indicators.

Process indicators are necessary to gather evidence that the implementing steps of additional risk minimisation measures have been successful. These process indicators should provide insight into what extent the programme has been executed as planned and whether the intended impacts on behaviour have been observed. Implementation metrics should be identified in advance and tracked over time. ~~The knowledge gained may be used to support corrective implementation action as needed.~~ Assessing the implementation process can also improve understanding of the process(es) and causal mechanism(s) whereby the additional risk minimisation measure(s) did or did not lead, to the desired control of specified important risks.

Outcome indicators provide an overall measure of the level of risk control that has been achieved with any risk minimisation measure in place. For example, where the objective of an intervention is to reduce the frequency and/or severity of an adverse reaction, the ultimate measure of success will be linked to this objective.

In rare circumstances when it is ~~fully~~ justified that the assessment of outcomes indicators is unfeasible (e.g. inadequate number of exposed patients, very rare adverse events), the effectiveness evaluation may be based exclusively on the careful interpretation of data on process indicators.

The conclusion of the evaluation may be that risk minimisation should remain unchanged or modifications are to be made to existing activities. Alternatively, the assessment could indicate that risk minimisation is insufficient and should be strengthened (e.g. through amendment of warnings or recommendations in the SmPC or package leaflet, improving the clarity of the risk minimisation advice and/or by adding additional tools or improving existing tools). Another decision may be that the risk minimisation is disproportionate or lacking a clear focus and could be reduced or simplified (e.g. by decreasing the number of tools or frequency of intervention, or by eliminating interventions proved to be non-contributory to risk minimisation). In all circumstances, the burden on the patient and the healthcare system should be given careful consideration.

In addition to assessing the effectiveness of risk minimisation measures in managing safety concerns, it is also important to monitor if the risk minimisation intervention may have had unintended (negative) consequences relevant to the public health question under consideration, either in the short and/or long term. Examples of unintended consequences may include undue burden on the healthcare system, or discontinuation of a product ~~in patients~~ even ~~if it is the~~ risk-benefit balance ~~remains was~~ positive ~~for them~~.

The legislation defines "Any study ....measuring the effectiveness of risk management measures" as a post-authorisation safety study [DIR Art 1 (15)]. Therefore, if a study is conducted to assess behavioural or safety outcome indicators the detailed guidance for conducting a post-authorisation safety study, which is provided in ~~GVP~~ Module VIII, should be followed. ~~Such This~~ guidance does not apply to the measurement of simple process markers (e.g. distribution of the tools reaching the target population). The ENCePP Guide on Methodological Standards in Pharmacoepidemiology<sup>2</sup> should be ~~considered-applied~~ as appropriate.

#### **XVI.B.4.1. Process indicators**

Process indicators are measures of the extent of implementation of the original plan, and/or variations in its delivery. Process indicators should complement but not replace the assessment of the attainment of the objectives of the risk minimisation measures (i.e. outcome indicators). Depending on the nature of the interventions various process indicators can be identified for the assessment of their performance.

---

<sup>2</sup> <http://www.encepp.eu>

#### **XVI.B.4.1.1. Reaching the target population**

When risk minimisation measures involve the provision of information and guidance to healthcare professionals and/or patients by means of educational tools, measures of distribution and receipt should be used to acquire basic information on implementation. These metrics should focus on assessing whether the materials were delivered to the target audience and whether they were actually received by the target population.

#### **XVI.B.4.1.2. Assessing clinical knowledge**

In order to assess the awareness of the target audience, their attitude and the level of knowledge achieved by educational interventions and/or other information provision (for example, e.g. via an educational programme with a goal of preventing drug exposure during pregnancy), scientifically rigorous survey methods should be applied. XVI. Appendix I summarises key methodological aspects to be considered for the design and implementation of a survey.

A survey generally includes a core-set of standard questions administered through telephone contact, in-person interview, or self-administered through postal/electronic communication, which are repeated over time. Such an approach may be tailored to the monitoring of attitude and knowledge in a diverse sample, that includes representatives from each audience segment of interest in the target populations of healthcare professionals and/or patients. Psychometric measures should be used as appropriate. Whenever feasible a randomised sample and an adequate sample size should be selected. In contrast, use of the advocacy groups or patient support groups to survey knowledge can be considered to be inherently biased through self-selection, and should be avoided.

Appropriate attention should be given to the research objectives, study design, sample size and representativeness, operational definition of dependent and independent variables, and statistical analysis. Thorough consideration should also be given to the choice of the most appropriate data collection instruments (e.g. questionnaires).

#### **XVI.B.4.1.3. Assessing clinical actions**

In order to evaluate the effectiveness of educational interventions and/or information provisions, not only clinical knowledge but also the resulting clinical actions (i.e. prescribing behaviour) should be measured. Drug utilisation studies by means of secondary use of electronic records or through medical chart abstraction are valuable options to quantify clinical actions, if representativeness of the target population and where adequate databases are accessible provided. The analysis of prescription records, especially when linked to other patients records of patients (e.g. clinical and/or demographic data), may allow the evaluation of prescribing behaviour, including co-prescribing of two interacting medicinal products, compliance with laboratory monitoring recommendations, as well as patient selection and monitoring. By applying appropriate statistical methods (e.g. time series analyses, survival analyses, logistic regression) to a cohort of medicines users, different aspects of prescribing or use may be assessed/analysed, which can provide insights beyond purely descriptive evidence. Careful consideration should be given to the conduct and interpretation of drug utilisation studies across Member States/countries, including the legal status of the medicine and how it is prescribed and dispensed, since prescription patterns may reflect not only the product information and any risk minimisation intervention, but also national guidelines, aspects related to healthcare services, local medical practice, and reimbursement constraints. Such a diversity of national healthcare delivery systems across the EU may justify the conduct of a study with the same objectives in multiple countries.

~~The study~~Studies of behaviour based on data collected through surveys should only be considered when no pre-existing data are available to evaluate clinical actions (i.e. conduct a drug utilisation study based on self-reported data collected in healthcare professionals and/or patients survey).

#### **XVI.B.4.2. Outcome indicators**

The ultimate measures of success of a risk minimisation programme are the safety outcomes, i.e. the frequency and/or severity of adverse reactions in relation to patients' exposure to the medicine outside of an interventional study setting (~~i.e. non-interventional setting~~) and ~~those~~these safety outcomes should be the outcome indicator(s). Such an evaluation should involve the comparison of epidemiologic measures of outcome frequency such as incidence rate or cumulative incidence of an adverse reaction, obtained, ~~e.g. for example~~in the context of post-authorisation safety studies. The use of appropriate safety-related outcomes of interest should be considered (e.g. a surrogate endpoint such as an adequate biomarker as a substitute for a clinical endpoint) if such an approach facilitates the effectiveness evaluation. Under any approach, scientific rigour and recognised principles of epidemiologic research should always guide the assessment of the final outcome indicator of interest. Comparisons of frequency before and after the implementation of the risk minimisation measures (i.e. pre-post design~~s~~) should be considered. When a pre-post design is unfeasible (e.g. ~~when~~ risk minimisation measures are put in place at the time of initial marketing authorisation), the comparison of an outcome frequency indicator obtained post-intervention against a predefined reference value obtained from literature review, historical data, expected frequency in general population, would be acceptable (i.e. observed versus expected analysis) and should take into account any stimulated reporting, changes in patient care and/or risk minimisation measures over time. The selection of any particular reference group should be ~~appropriately~~justified.

Methods to measure the effectiveness of risk minimisation measure should be proportionate to the risks being minimised. As such use of spontaneous reporting rates (i.e. number of suspected adverse reaction reports over a fixed time period) may be acceptable in the context of routine risk minimisation. Spontaneous reporting should be considered with caution ~~when~~estimating the frequency of adverse events in the treated population, ~~while but~~it may be ~~used~~useful in very specific circumstances, for instance when the adverse reaction with the product is rare, ~~and there is a negligible~~the background incidence of the adverse event in the general population ~~negligible~~ and a strong association between treatment and the adverse event. In those circumstances when a direct measure on the risk in the treated population is not feasible, spontaneous reporting could offer an approximation of the frequency of the adverse reaction in the treated population, provided that reasonably valid data can be obtained to evaluate the reporting rate in the context of product use. However, the well-known biases that affects reporting of suspected adverse reactions may provide misleading results. For instance, the introduction of a risk minimisation measure in response to a safety concern detected in the post-authorisation phase of a medicinal product may raise awareness regarding ~~selected-related~~adverse reactions which ultimately may result in an increased reporting rate. In these circumstances an analysis of spontaneous reporting may lead to the erroneous conclusion that the intervention was ineffective. Decreasing reporting rates over time may also lead to the erroneous conclusion that the intervention was effective.

#### **XVI.B.5. Coordination**

If several products, including medicinal products authorised according to ~~art.~~Articles 10(1) or 10(3) of Directive 2001/83/EC (herein referred to as "generics" or "hybrids", as appropriate), of the same active substance are available ~~in on~~a market, there should be a consistent approach in the use of additional risk minimisation measures coordinated and overseen by the ~~national~~competent authorities.

When a coordinated action for a class of products is needed a harmonised approach should be agreed if appropriate. Under these circumstances advanced planning should ensure that the effectiveness of risk minimisation measures (see XVI.B.4.) can be considered for each individual product as well as for the products collectively.

### **XVI.B.6. Quality systems of risk minimisation measures**

Although many experts may be involved in developing and implementing risk minimisation measures, the final responsibility for the quality, accuracy and scientific integrity of those measures and the plan describing them lies with the marketing authorisation holder and its qualified person responsible for pharmacovigilance ~~in the EU~~ (QPPV).

The marketing authorisation holder is responsible for updating the RMP when new information becomes available and should apply the quality principles detailed in [GVP Module I](#). Tracked versions of the RMP should be submitted to facilitate regulatory assessment. These records, the RMP and the associated risk management systems, as well as any documents on risk minimisation measures may be subject to audit or inspection ([see GVP Module III](#)).

The marketing authorisation holder should ensure appropriate version control of the risk minimisation tools in order to ensure that all healthcare professionals and patients receive up-to-date risk minimisation tools in a timely manner and that the tools in circulation are consistent with the approved product information. ~~To~~ For this purpose the market authorisation holders are encouraged to keep track of the receipt of any risk minimisation tools [by target audience](#). These records may be subject to audit and inspection.

The marketing authorisation holder should ensure that mechanisms for reporting the results of studies or analyses for evaluation of the effectiveness of risk minimisation measures are documented. These may be subject to audit or inspection.

### **XVI.C. Operation of the EU ~~regulatory~~ network**

For centrally authorised products additional risk minimisation measures recommended by the Pharmacovigilance Risk Assessment Committee (PRAC) and agreed by the Committee for Medicinal Products for Human Use (CHMP) will become, once agreed by the European Commission [through a Commission decision](#), conditions for the safe and effective use of a medicinal product.

Annex II of the CHMP opinion will outline the key elements of any additional risk minimisation measures imposed on the applicant or marketing authorisation holder as a condition for the safe and effective use of a medicinal product. [Because of the specificities of the healthcare systems in Member States and of how particular risk\(s\) are managed within these systems, some risk minimisation measures may need to be implemented differently depending on national feasibility and require additional agreement with the Member States \(e.g. pregnancy prevention programmes, controlled distribution\). Therefore, for centrally authorised products, the legislation foresees that in addition to the Commission decision addressed to the marketing authorisation holder under Article 127a of Directive 2001/83/EC, there can be a Commission decision addressed to the Member States giving them the responsibility for ensuring that specific conditions and/or restrictions are implemented by the marketing authorisation holder in their territory.](#)

~~Therefore, An~~ annex [in a Commission decision](#) related to Article 127a of [Directive 2001/83/EC](#) ~~can~~ may describe the responsibilities of national competent authorities in ensuring that the additional risk minimisation measures are implemented in the Member States in accordance with defined key

elements. Further details or key elements on any additional risk minimisation measures ~~may should~~ also be included in annex ~~10-6~~ of the RMP (see GVP Module V).

For products authorised under the mutual recognition and decentralised procedure, additional risk minimisation measures ~~may should~~ be included in annex 6 of the RMP ~~or and may also be~~ laid down as conditions of the marketing authorisation.

In all cases, implementation of additional risk minimisation measures takes place at national level and allows Member States to tailor the required conditions and restrictions to any national legal requirements and local healthcare systems.

### **~~XVI.C.1. Roles and responsibilities within in the EU for implementing additional risk minimisation measures~~ regulatory network**

This section outlines the responsibilities of different bodies ~~as having clear obligations. This includes the Agency and its PRAC, national competent authorities, and the applicant or marketing authorisation holder~~ in the process of developing, implementing and evaluating additional risk minimisation measures introduced for the safe and effective use of a medicinal product in the EU.

In order to respect the diversity of ~~EU the different~~ health care systems in Member States, key elements will be agreed at EU level, which need to be implemented in a coordinated manner across the Member States while providing for agreement of the detail of local implementation at national level. In circumstances where some key elements are specific for only some Member States (e.g. an activity is specifically linked to the healthcare system of one Member State) or where additional risk minimisation measures are not imposed as a condition for marketing authorisation these shall be included in the RMP.

#### ~~XVI.C.1.1. Roles and responsibilities within the EU regulatory network~~

##### ~~XVI.C.1.1.1. The European Medicines Agency~~

The Agency shall, in collaboration with the Member States and facilitated through the PRAC, monitor the outcome of risk minimisation measures contained in RMPs and of conditions referred to in points (c), (ca), (cb) and (cc) of Article 9(4) or in points (a) and (b) of Article 10a(1), and in Article 14(7) and (8) of Regulation (EC) No 726/2004 [REG Art 28a(1)(a)].

In monitoring the outcome of risk minimisation measures, the Agency should support the PRAC scientific assessment of the outcome of risk minimisation measures which comprise additional risk minimisation measures, through the integration of data provided by Member State resources and research activities. The PRAC will make recommendations to the CHMP or the Coordination Group – Human (CMDh), as appropriate, regarding any necessary regulatory action.

##### ~~XVI.C.1.1.2. The Pharmacovigilance Risk Assessment Committee (PRAC)~~

The PRAC should evaluate the outcome of risk minimisation measures, including additional risk minimisation measures and make recommendations as appropriate regarding any necessary regulatory action.

In addition to advising on the studies and measures described in the RMP, the PRAC will assess both protocol and results of imposed post-authorisation safety studies which aim to evaluate the effectiveness of risk minimisation measures (see GVP Module VIII).



### **XVI.C.1.1-3. Competent authorities in Member States**

The national competent authorities are responsible for the oversight at national level of the implementation of additional risk minimisation measures imposed as a condition of the marketing authorisation for the safe and effective use of a medicinal product in the EU, irrespective of the route of marketing authorisation.

For those risk minimisation measures introduced after the initial marketing authorisation, the national competent authorities should ensure prompt consideration and agreement of the interventions with the marketing authorisation holder.

The national competent authorities assisted by the PRAC and CHMP or CMDh, as appropriate, may facilitate ~~harmonization~~ harmonisation of the implementation of risk minimisation tools for generic products of the same active substance. When additional risk minimisation measures are considered necessary for generic medicinal product(s) based on safety concerns related to the active substance, the risk minimisation measures applicable to the generic product(s) should be aligned with those for the reference medicinal product. Additional risk minimisation measures for hybrid products may be required in some circumstances beyond those of the reference medicinal product (e.g. different formulation or route of administration or incompatibility issues). To facilitate this, the PRAC may give advice on the key elements that should be implemented for all concerned nationally authorised products (as conditions of their marketing authorisation) and on agreement, may make these general requirements publicly available to facilitate harmonised implementation at national level.

In addition to the above, for centrally authorised products the responsibility of the national competent authorities in ensuring implementation of the risk minimisation measures ~~may be as-~~ addressed to them by ~~the European means of~~ Commission decision ~~may be outlined in the annex related to under~~ Article 127a of Directive 2001/83/EC ~~IR. In the absence of such an annex, the general responsibilities of supervisory authorities will apply.~~

Additionally, the national competent authorities should agree the final content, format and media of the risk minimisation tools, including printed material, web-based platforms and other audio-video media, as well as the schedule planning of interventions with the applicant or marketing authorisation holder before a product is introduced to their market or at any time thereafter as needed (see GVP Module XVI – Addendum I).

The national competent authority ~~is autonomous in deciding~~ decides appropriate national educational materials and/or other risk minimisation tools as long as these are aligned with the key elements agreed at EU level and as outlined in the RMP (see GVP Module XVI – Addendum I). Similarly, measurement of effectiveness of additional risk minimisation measures may be required in one Member State in reason of its specific health care delivery setting or when, due to national specificities, results of the effectiveness studies cannot be extrapolated from studies conducted in other Member States.

National competent authorities in collaboration with the Agency facilitated through the PRAC shall monitor at national level the outcome of risk minimisation measures contained in RMPs and of the conditions referred to in Articles 21a, 22 or 22a of Directive 2001/83/EC ~~IR~~ [DIR Art 107h(1)(a)].

Where patient alert cards (see XVI.B.2.1.1.2.) are included in the outer packaging, they are considered as part of the labelling, therefore the text and the format should be agreed by the authorising competent authority (full text included in Annex III of the marketing authorisation).

For centrally authorised products, when specific national circumstances are required (e.g. multilingual documents), the patient alert card might not fit a wallet format. In such a case the card might not be

included in the product package and should not be considered as part of the labelling. In this case, the national competent authorities should agree on the final content and format, as for other additional risk minimisation activities.

### **XVI.C.1-2. Roles and responsibilities of the marketing authorisation holder or applicant in the EU marketing authorisation applicant or holder**

Marketing authorisation applicants/holders in the EU are responsible for ensuring compliance with the conditions of the marketing authorisation for their products wherever they are used within the EU. It is the responsibility of the marketing authorisation holder to implement all conditions or restrictions with regard to the safe use of the product in a particular territory.

The applicant or marketing authorisation holder should clearly define the objectives of any proposed additional risk minimisation measure and the indicators to assess their effectiveness. The applicant or marketing authorisation holder is encouraged to discuss risk minimisation plans with the competent authorities in Member States as early as is feasible, e.g. when it seems likely that specific risk minimisation activities will need to be adapted to the different healthcare systems in place in the different Member States.

Any additional risk minimisation intervention should be developed in accordance with the general principles outlined in XVI.B.1. and XVI.B.2. and should be fully documented in the RMP (see GVP Module V).

The measures adopted in the RMP should be implemented by the marketing authorisation holder at national level after agreement with the national competent authorities.

The applicant or marketing authorisation holder should provide information regarding the status of implementation of additional risk minimisation measures as agreed with the national competent authorities and keep them informed of any changes, challenges or issues encountered in the implementation of the additional risk minimisation measures. Any relevant changes to the implementation of the tools should be agreed with the national competent authorities before implementation.

In the implementation of web-based tools the applicant or marketing authorisation holder should apply requirements specific for each Member State, with particular consideration of potential issues linked to accessibility, recognisability, responsibility, and privacy and data protection.

For generic products the applicant or marketing authorisation holder should develop risk minimisation in line with the scope, content, and format of the tools used for the reference medicinal product. Scheduling and planning of interventions should be carefully coordinated in order to minimise the burden on the healthcare systems.

~~For generic products, the effectiveness of risk minimisation measures should be assessed by the marketing authorisation holders in close cooperation with the competent authorities. Where formal studies are justified, joint studies for all medicinal products involved are strongly encouraged in order to minimise the burden on the healthcare systems. For instance, if a prospective cohort study is instituted, study entry should be independent from the prescription of a product with a specific invented name or marketing authorisation holder. Recording of specific product details would still be important to enable rapid identification of any new safety hazard with a particular product.~~

The marketing authorisation holder shall monitor the outcome of risk minimisation measures which are contained in the RMP or which are laid down as conditions of the marketing authorisation pursuant to

Articles 21a, 22 or 22a of DIR [DIR Art 104(3)(d)]. General principles for effectiveness evaluation are provided in [XVI.B.3.](#)

The applicant or marketing authorisation holder should report the evaluation of the impact of additional risk minimisation activities when updating the RMP (see [V.B.11.4.](#)).

The applicant or marketing authorisation holder should report in the Periodic Safety Update Report (PSUR) the results of the assessment of the effectiveness of risk minimisation measures which might have an impact on the safety or risk-benefit assessment (see [VII.B.5.16.5.](#) and [VII.C.5.5.](#)).

For generic products, the effectiveness of risk minimisation measures should be assessed by the marketing authorisation holders in close cooperation with the competent authorities. Where formal studies are justified, joint studies for all medicinal products involved are strongly encouraged in order to minimise the burden on the healthcare systems. For instance, if a prospective cohort study is instituted, study entry should be independent from the prescription of a product with a specific invented name or marketing authorisation holder. Recording of specific product details would still be important to enable rapid identification of any new safety hazard with a particular product.

The applicant or marketing authorisation holder should ensure timely communication with the competent authorities for relevant regulatory evaluation and actions, as appropriate (see also [XVI.C.2.](#) and [GVP Modules V and VII](#)).

### ***XVI.C.3. Healthcare professionals and patients***

Healthcare professionals and patients hold no legal obligations with respect to the implementation of the pharmacovigilance legislation. Nonetheless the cooperation of healthcare professionals and patients is paramount to the success of educational programmes and/or controlled access programmes in order to optimise the risk-benefit balance. It is desirable that they give careful consideration to any additional risk minimisation measure which may be introduced for the safe and effective use of medicines.

### ***XVI.C.4. Impact of risk minimisation measures effectiveness on RMP/PSUR in the EU***

PSUR and RMP updates should include a summary evaluation of the outcome of specific risk minimisation measures implemented to mitigate important risks in the EU. In the RMP, the focus should be on how this informs risk minimisation and/or pharmacovigilance planning. In the PSUR, there should also be evaluation of how the implemented measures impact on the safety profile and/or risk-benefit balance of the product. In general, the focus should be on information which has emerged during the reporting period or since implementation of the most recent risk minimisation measure(s) in the EU. Where there is parallel submission of a PSUR and an RMP update [to the competent authorities of the EU regulatory network](#), the use of a common content [Module-module](#) should be considered (see [GVP Modules V and VII](#)). [For the evaluation, the guidance in XVI.B.4 applies.](#)

Results of the assessment(s) of the effectiveness of risk minimisation measures should always be included in the RMP. As part of this critical evaluation, the marketing authorisation holder should make observations on factors contributing to the success or weakness of risk minimisation measures. This critical analysis may include reference to experience outside the EU, [when where](#) relevant.

The evaluation of the effectiveness of risk minimisation measures should focus on whether these have succeeded in minimising risk. This should be analysed using a combination of process and outcome indicators, as described in [XVI.B.3.](#) It may be appropriate to distinguish between risk minimisation

measures implemented at the time of initial marketing authorisation and those introduced later in the post-authorisation phase.

When presenting the [outcome of an](#) evaluation of the effectiveness of a risk minimisation measure, the following aspects should be considered:

1. The evaluation should provide context by a) briefly describing the implemented risk minimisation measure(s), b) defining their objective(s), and c) outlining the selected process and outcome indicators.
2. The evaluation should incorporate relevant analyses of the nature of the adverse reaction(s) including its severity and preventability. Where appropriate logistical factors which may impact on clinical delivery of the risk minimisation measure should also be included.
3. The evaluation should include an examination of the delivery of the risk minimisation measures in routine clinical practice, including any deviation from the original plan. Such an evaluation may include the results of drug utilisation studies.
4. Outcome indicators (~~(i.e. adverse reaction frequency and/or severity; other safety-related outcomes)~~) should normally be the key endpoint when assessing the attainment of risk minimisation measures objectives.

Proposals for changes to enhance risk management should be presented in the regional appendix of the PSUR (see [GVP Module VII.C.5](#)). The RMP should be updated to take account of emerging information on the effectiveness of risk minimisation measures.

In general, generic products are exempt from routine PSUR reporting in the EU. The frequency of RMP updates should be proportionate to the risks of the product. In general, the focus of RMP updates should be on the risk minimisation measures and in providing updates on the implementation of those measures where applicable. If there is a consequential change to the summary RMP, this should also be highlighted in the cover letter. Changes to the product information should not be proposed via a standalone RMP update, but rather a variation application should be submitted. A PSUR can also result directly in an update to product information (if PSURs are being submitted by the marketing authorisation holder for a given generic product).

### ***XVI.C.5. Transparency***

Procedures should be in place to ensure full transparency of relevant information pertaining to the risk minimisation measures in place for the concerned medicinal products.

In accordance with Article 106 of Directive 2001/83/EC and Article 26 of Regulation (EC) No 726/2004, the Agency and national competent authorities shall make publicly available public assessment reports for medicinal products, as well as summaries of RMPs (~~Commission Implementing Regulation (EU) No 520/2012~~, [IR Art 31], including risk minimisation measures therein described.

For centrally authorised products, the Agency shall make public:

- a summary of the risk management plan [REG Art 26(1)(c)], with specific focus on risk minimisation activities described therein [IR Art 31.1];
- the European Public Assessment Report (EPAR) that includes any conditions of the marketing authorisation, such as additional risk minimisation measures [REG Art 26(1)(j)].

By means of the national medicines web-portals, the Member States shall make publicly available at least the following:

- public assessment report; this shall include a summary written in a manner that is understandable to the public [DIR Art 21(4), Art 106(a)];
- summary of product characteristics and package leaflets [DIR Art 21(3), Art 106(b)];
- conditions of the marketing authorisation together with any deadlines for the fulfilment of those conditions [DIR Art 21(3)];
- summaries of risk management plans [DIR Art 106(c)]; with specific focus on risk minimisation activities described therein [IR Art 31.1].

To promote public health, it is recommended that the Agency and the national competent authorities make the following information available via their websites:

- details of additional risk minimisation measures required as a condition of the marketing authorisation (e.g. when risk communication tools consist of printed material, a copy is provided or whenever possible, provision of electronic access to the educational material, patient card, check lists or other risk minimisation tools is advised);
- details of disease or substance registries requested as part of a restricted distribution system.

## XVI. Appendix 1. Key elements of survey methodology

Surveys are ~~systematic~~ methods of ~~systematically~~ collecting primary data directly from a sample of participants ~~from of~~ a larger population. These are conducted in order to characterise the larger population and may be cross-sectional (one-time only) or longitudinal (repeated over time).

In the context of the evaluation of the effectiveness of risk minimisation measures a survey can be conducted to evaluate understanding, knowledge and behaviour resulting from educational interventions in a specified target population with respect to the safety and risk management of a medicinal product.

~~The A~~ survey ~~methodology~~ might not be the most appropriate approach for the evaluation of behaviour, since surveys ~~often~~ collect and analyse self-reported data from healthcare professionals and patients. Furthermore, participation in a survey in itself may introduce behaviour changes or may not be representative of the target users given that participation is more likely amongst engaged healthcare professionals and/or more motivated or educated individuals.

As a minimum, the following elements should be considered in the design and implementation of a survey ~~in order with a view~~ to minimise potential biases and to optimise the generalisability of the results to the intended population:

1. ~~Sampling~~ ~~sampling~~ procedures and recruitment strategy;
2. ~~Design~~ ~~design~~ and administration of the data collection instrument (s);
3. ~~Analytical~~ ~~analytical~~ approaches;
4. ~~Ethics~~ ~~ethics~~, privacy, and overall feasibility of a study.

### **XVI.App1.1. Sampling procedures and recruitment strategy**

In any survey, the sampling frame and recruitment of participants may be subject to selection bias leading to a study population that is not similar to, or representative of, the intended population in one or more aspects. Furthermore, it should be considered that a bias cannot be eliminated only by increasing the sample frame, sample size and response rate. Bias can be minimised by selecting the optimal sampling frame, taking into account age, sex, geographical distribution and additional characteristics of the study population. Bias can also be minimised by assuring the sample contains appropriate diversity to allow stratification of results by key population characteristics (e.g., by oversampling a small but important subgroup). Key elements to be considered in the sampling frame include age, gender, geographical distribution, and additional characteristics of the study population. For example, in a physician survey, the strategy for randomly selecting the study sample should consider whether a general random sample would be sufficient or if the sample should be stratified by key characteristics such as specialty, type of practice (e.g., primary care, specialist ~~ward~~ ~~care~~, academic ~~institution~~ ~~hospital~~). In a patient survey, income and education, medical condition(s), chronic vs acute use, should be considered.

In addition to the overall representativeness of the target population the recruitment strategy of a survey should give careful consideration of the potential recruitment sources. For the recruitment of healthcare professionals, sponsor lists, web panels, professional and learned societies may represent feasible approaches. However, their representativeness for the intended target population of physicians needs to be carefully reviewed for each study. For patient recruitment the relevant clinical setting, ~~and~~ ~~existing~~ ~~web-panels~~, ~~and~~ ~~patient~~ ~~advocacy~~ ~~groups~~ should be considered. A recruitment strategy should be designed while accounting for the chances of achieving accurate and complete data collection.

Efforts should be made to document the proportion of non-responders and their characteristics to evaluate potential influences on the representativeness of the sample.

### ***XVI.App1.2. Design and administration of the data collection instrument(s)***

Data collection approaches in a survey may vary from in-person interview, testing, and measurement or collection of biological samples as for routine clinical practice, to telephone interview, web-based or paper-based questionnaires. Audio computer-assisted self-interviewing (A-CASI), interactive voice response systems (IVRS), or mixed mode approaches may also be appropriate. The choice of the most suitable data collection approach will depend on the target population characteristics, the disease and the treatment characteristics and the [type of](#) data to be collected.

Each data collection approach will require the ad hoc design of one or more specific instruments. Nonetheless general design considerations that may apply to all instruments include the following:

- ~~Burden~~[burden](#) to participant~~+~~[-](#) e.g. length or duration, cognitive burden, sensitivity to participant;
- ~~Clarity~~[clarity](#) and sequence of questions~~+~~[-](#) e.g. use of unambiguous language, minimising assumptions, starting with the most important questions and leaving sensitive questions until later;
- ~~Completeness~~[completeness](#) of responses~~+~~[-](#) e.g. structure questions in order to lead to a single unambiguous answer, allow for choices such as “unknown” or “don’t know”;
- ~~Layout~~[layout](#) of data collection instrument~~+~~[-](#) e.g. clear flow, technology-assisted guides (avoid patterns, reminders for non-response and visual images);
- ~~Testing~~[testing](#) and revision of instrument~~+~~[-](#) e.g. formal testing using cognitive pre-testing such as one-to-one interviews, probing questions, interview guide or trained interviewer, and “think aloud” process;
- ~~Incentives~~[incentives](#) to improve response rate~~+~~[-](#) e.g. fed back aggregated data to the survey participants.

### ***XVI.App1.3. Analytical approaches***

The key analytical elements of a survey should include:

- ~~Descriptive~~[descriptive](#) statistics, such as:
  - ~~The~~[the](#) percentage of participants responding correctly to knowledge questions;
  - ~~Stratification~~[stratification](#) by selected variable;
  - ~~Data~~[data](#) on no-response or incomplete response;
- ~~Comparison~~[comparison](#) of responders and non-responders characteristics (if data available);
- ~~Comparison~~[comparison](#) of responders and overall target population characteristics.

When survey results are weighted, the following key points should be considered:

- ~~Differences~~[differences](#) in selection probabilities (e.g. if certain subgroups were over-sampled);
- ~~Differences~~[differences](#) in response rates;
- ~~Post~~[post](#)-stratification weighting to the external population;
- ~~Clustering~~[clustering](#).

Examples of stratified analyses of physician's survey include the following:

- ~~Specialty~~ [specialty](#) of physician;
- ~~Geographic~~ [geographic](#) location;
- ~~Receipt~~ [receipt](#) of any educational material;
- ~~Volume~~ [volume](#) of prescribing.

#### **XVI.App1.4. Ethics, privacy and overall study feasibility**

Ethical and data privacy requirements are not harmonised across Member States ~~and have, with~~ notable differences in national (or regional) processes. National (or regional) differences may exist regarding the appropriateness of providing incentives to survey participants. There may also be privacy considerations in allowing contact with physicians based on a prescriber list that is held by ~~a~~ [pharmaceutical company marketing authorisation holder](#).

The overall feasibility assessment of a study is a key step in the successful implementation of a survey. For clinical-based data collection, key elements of such an assessment include:

- ~~Gathering~~ [gathering](#) information on site and characteristics of study population (patients or healthcare professionals);
- ~~Estimating~~ [estimating](#) reasonable study sample size, the number of sites required to achieve the sample size, and approximate length of the data collection period (e.g. based on estimated patient volume, frequency of patient visits, and expected patient response rate);
- ~~Evaluating~~ [evaluating](#) site resources and interest in the study.

Key elements of a feasibility assessment may be different for other study designs (e.g. web-based recruitment and data collection) and for physician assessments.